Trademark Overview
On Tuesday, March 7, 2023, a trademark application was filed for OSSRINTA with the United States Patent and Trademark Office. The USPTO has given the OSSRINTA trademark a serial number of 97826064. The federal status of this trademark filing is ABANDONED - EXPRESS as of Wednesday, May 24, 2023. This trademark is owned by Fresenius Kabi Deutschland GmbH. The OSSRINTA trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment of oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for the prevention of fractures; pharmaceutical preparations for human use for prevention of pain associated with oncological and metabolic diseases and disorders; pharmaceutical preparations for human use for surgery, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for radiotherapy, namely, for prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; pharmaceutical preparations for human use for the treatment and prevention of bone metastases, solid tumors, osteolytic bone lesions of multiple myeloma, hypercalcemia of malignancy, giant cell tumor of bone
